Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance
- 31 July 1992
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 16 (6-7) , 673-680
- https://doi.org/10.1016/0145-2126(92)90018-3
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevanceBritish Journal of Haematology, 1991
- The CD2-LFA-3 and LFA-1-ICAM pathways: relevance to T-cell recognitionImmunology Today, 1989
- Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remissionBlood, 1989
- In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantationBlood, 1989
- Functional analysis of cytotoxic cells in patients with acute nonlymphoblastic leukemia in complete remissionCancer, 1989
- Induction of lymphokine-activated killer cells against human leukemia cells in vitroAnnals of Hematology, 1989
- Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cellsEuropean Journal of Haematology, 1988
- Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remissionBlood, 1988
- Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cellsBlood, 1986
- Lymphokine activated killing of fresh human leukaemiasLeukemia Research, 1986